

2nd International Summit on **TOXICOLOGY** October 07-09, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

Metabolomics reveals the novel mechanism of drug toxicity

Feng Li University of Kansas Medical Center, USA

Drug-induced toxicity is a big issue in the clinical practice. Most drugs may cause adverse drug reactions, in small portion of patients. Understanding the mechanism could help us to predict, prevent, and treat the drug-induced toxicity. Although lots of researches have been done in this field, unfortunately, very few mechanisms are known. In recent couple decades, different "-omics" are used to investigate the mechanism of drug-induced toxicity, for example, genomics and proteomics. These omics could provide us the information at gene and protein level, respectively. The newly emerging metabolomics has been employed, which could tell us what already happened at molecular level. Currently, my researches integrate LC-MS-based metabolomics and mouse models to investigate the mechanism of drug induced toxicity and drug metabolism. Using a metabolomic approach and Pregane X receptor (PXR)-humanized mice, I found that co-treatment with rifampicin and isoniazid (anti-tuberculosis drugs) causes accumulation of the endogenous hepatotoxin protoporphyrin IX in the liver through PXR-mediated alteration of the heme biosynthesis pathway. The novel mechanism provides insight into the mechanism of liver injury associated with co-therapy. Mechanisms of drug induced toxicity are very complicated, because drug combination, species differences, and individual difference make them more complex. In the future, integration of different omics and animal models are beneficial to investigate the mechanism of drug induced toxicity.

Biography

Feng Li has completed his Ph.D. in Organic Chemistry from Universität Stuttgart, Germany. From 2007 to 2009, He worked in Medicinal Chemistry at National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH) as a visiting fellow. Currently, he is a research assistant Professor in the Department of Pharmacology at the University of Kansas Medical Center. He has published more than 22 papers in the reputed journals and has been serving as reviewer of several reputed journals.

fli2@kumc.edu